CONMED'S $16.4 MIL STOCK SWAP ACQUISITION OF BIRTCHER
This article was originally published in The Gray Sheet
Executive Summary
CONMED'S $16.4 MIL STOCK SWAP ACQUISITION OF BIRTCHER values Irvine, California-based electrosurgical products manufacturer Birtcher Medical Systems at less than half its fiscal 1994 sales and represents a 12% premium over Birtcher's Dec. 5 NASDAQ closing price of $1-1/8 per share. The two companies announced on Dec. 6 the signing of a definitive merger agreement by which Birtcher shareholders will receive 1/12 of a share of Conmed common stock for each Birtcher common share and 1/2 of a Conmed common share for each share of Birtcher preferred stock. At Conmed's Dec. 5 closing price of 22-3/4, Birtcher would receive $1.26 per common share.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.